Here’s our Summer 2022 Roundup of top Maryland life sciences companies with more than 10 active job listings across a wide range of fields and experience levels.
After a major boom spurred by the pandemic investment and the emergence of a host of promising cell and gene therapy companies, the life sciences—along with a multitude of other business segments—are feeling the downward push fomented by the pandemic, war, inflation, and the subsequent higher cost of goods.
There are several incubators across the region that have proven to be a fantastic option for biohealth startup companies. These incubators provide the right mix of services, amenities and mentorship programs that help young companies navigate complex processes, find their way and succeed.
The buzz around the summit was one of enthusiasm as Philly strives to join the top tier of life sciences hub in the country. The life sciences scene in Philly is growing and may soon be approaching an inflection point preceding rapid growth, reminiscent of 1990s Boston. The Summit examined the dynamic Philly landscape as a whole, both celebrating recent successes and talk about the hurdles that must be overcome for the ecosystem to truly thrive.
Fueled by its own success and growth over the past 12 months, including the opening of a new CLIA laboratory facility in Gaithersburg, 20/20 GeneSystems is now lending a helping hand to other diagnostic startups across the area.
Using its powerful artificial intelligence-driven Concentriq digital pathology platform, Proscia is accelerating breakthroughs in precision medicine. David West, Co-Founder and Chief Executive Officer of Proscia, explained that pathology has been a core component of research and diagnosis for more than 150 years. But, with advances in technology and machine learning capabilities, the field is shifting away from microscopes and glass slides and becoming a data-driven discipline that is more reliant on the use of high-resolution digital imagery.
After achieving several important clinical milestones, momentum and excitement has been building for months around the company’s lead pipeline candidate AGT103-T, which is a potential HIV functional cure. In the coming months, the company expects to have the latest data readout for its Phase I trial. AGT103-T is a single-dose HIV gene therapy that could potentially replace antiretroviral therapy (ART) with a functional cure.
Over a period of four days, life sciences companies from across the globe will descend on San Diego for the annual Biotechnology Innovation Organization (BIO) meeting. Multiple companies from Maryland, as well as the Department of Commerce, will be among them, showcasing the strength of the BioHealth Capital Region.
Today, a host of life sciences companies are utilizing gene therapy as a tool to find a cure for HIV. When discussing an HIV cure, there are two different possible targets: a “functional cure” where HIV is not eradicated but rather totally controlled without further ART treatment and a “sterilizing cure” that eliminates HIV completely from the body.
ASCO 2022 press releases from the BioHealth Capital Region and Greater Philadelphia